nivolumab,ramucirumab,avapritinib,regorafenib
eli lilly,bms,blueprint medicines
['nivo', 'ramucirumab', 'nivolumab', 'gastric']
this just in from #asco22! findings from the voyager phase ii study patients with advanced gastric cancer who receive early induction of nivolumab with 2l taxane ramucirumab have better progression-free survival at 6 months. 